Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CLINICAL TRIALS

A new era of treatment for primary hyperoxaluria type 1

Nature Reviews Nephrology volume 17, pages 573–574 (2021)Cite this article

Subjects

New data from the ILLUMINATE-A trial of lumasiran demonstrate the safety and efficacy of this RNA interference therapeutic in patients with primary hyperoxaluria type 1. Further studies are required to investigate the potential long-term benefits of this promising therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Targeting hepatic glyoxylate metabolism in primary hyperoxaluria type 1.

References

  1. Garrelfs, S. et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N. Engl. J. Med. 384, 1216–1226 (2021).

    Article  CAS  Google Scholar 

  2. Danpure, C. J., Jennings, P. R. & Watts, R. W. E. Enzymological diagnosis of primary hyperoxaluria type I by measurement of hepatic alanine: glyoxylate aminotransferase. Lancet 329, 289–291 (1987).

    Article  Google Scholar 

  3. Danpure, C. J. et al. An enzyme trafficking defect in two patients with primary hyperoxaluria type 1: peroxisomal alanine/glyoxylate aminotransferase rerouted to mitochondria. J. Cell. Biol. 108, 1345–1352 (1989).

    Article  CAS  Google Scholar 

  4. Garrelfs, S. F. et al. Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int. 96, 1389–1399 (2019).

    Article  CAS  Google Scholar 

  5. Belostotsky, R. et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am. J. Hum. Genet. 87, 392–399 (2010).

    Article  CAS  Google Scholar 

  6. Mandrile, G. et al. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int. 86, 1197–1204 (2014).

    Article  CAS  Google Scholar 

  7. Monico, C. G. et al. Pyridoxine effect in type 1 primary hyperoxaluria is associated with the most common mutant allele. Kidney Int. 67, 1704–1709 (2005).

    Article  CAS  Google Scholar 

  8. Santana, A., Salido, E., Torres, A. & Shapiro, L. J. Primary hyperoxaluria type 1 in the Canary Islands: a conformational disease due to I244T mutation in the P11L-containing alanine: glyoxylate aminotransferase. Proc. Natl Acad. Sci. 100, 7277–7282 (2003).

    Article  CAS  Google Scholar 

  9. Hoyer-Kuhn, H. et al. Vitamin b6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. Clin. J. Am. Soc. Nephrol. 3, 468–477 (2014).

    Article  Google Scholar 

  10. Luzzatto, L. et al. Outrageous prices of orphan drugs: a call for collaboration. Lancet 392, 791–794 (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Human Genetics, Center for Molecular Medicine Cologne, Center for Rare Diseases Cologne, University of Cologne, University Hospital of Cologne, Cologne, Germany

    Florian Erger & Bodo B. Beck

Authors
  1. Florian Erger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bodo B. Beck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bodo B. Beck.

Ethics declarations

Competing interests

B.B.B. is a member of the scientific advisory board and has received personal fees from Alnylam Pharmaceuticals that are not related to this article. F.E. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Erger, F., Beck, B.B. A new era of treatment for primary hyperoxaluria type 1. Nat Rev Nephrol 17, 573–574 (2021). https://doi.org/10.1038/s41581-021-00449-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-021-00449-9

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing